Scholarlink

Purpose <p>Multivisceral surgical resections (MVR) are highly specialised procedures involving multidisciplinary surgical teams. MVR can be performed to achieve a complete oncological resection of tumours or to achieve cytoreductive surgery. The aim of the study is to evaluate the peri-operative outcomes of patients undergoing oncological multivisceral or multi-tissue resection which involved concomitant resection of the upper digestive tract/organs (oesophagogastric and hepatopancreatic-biliary).</p> Methods <p>This is a retrospective cohort study of patients treated between May 2019 to May 2023 at the Royal Marsden Hospital, London, United Kingdom. All treatment decisions were ratified at tumour specific multidisciplinary team meetings (MDT).</p> Results <p>A total of twenty-two patients were included in this series. The mean age and BMI were 56.2 years and 26.5&#xa0;kg/m<sup>2</sup> respectively. 86% of patients had ASA Grade II and 91% had WHO performance status of zero or one. 59% of patients underwent some form of tumour specific neoadjuvant treatment prior to surgical resection. The indication for surgery was due to malignancies originating from the upper digestive tract (41%), gynaecological organs (32%) and urinary tract (22%). The majority of cases (68%) involved surgeons from two sperate surgical specialties. 91% of cases involved resection of at least three or more organs or soft tissue groups. The mean critical care length of stay and total length of hospital stay was 2.9 days and 17.8 days respectively. 41% patients required inpatient blood transfusion. Clavien-Dindo Grade II, III and IV complication rates were 68%, 14% and 0% respectively. There were no 30-day re-admissions and no 90-day mortalities. The mean duration of follow up was 23.7 months. At time of analysis, the median overall survival (OS) was 21.0 months.</p> Conclusions <p>Complex MVR can be performed safely with acceptable perioperative outcomes at specialist high-volume centres. To achieve these outcomes patients should be selected carefully on a case-by-case basis with discussion at all respective tumour specific MDTs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multidisciplinary multivisceral resections involving the upper digestive tract: a United Kingdom tertiary cancer centre experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Kai Tai Derek Yeung,
  • Roumaysaa Bouyardan,
  • Desmond Barton,
  • David Nicol,
  • Sacheen Kumar,
  • Ricky Harminder Bhogal

摘要

Purpose

Multivisceral surgical resections (MVR) are highly specialised procedures involving multidisciplinary surgical teams. MVR can be performed to achieve a complete oncological resection of tumours or to achieve cytoreductive surgery. The aim of the study is to evaluate the peri-operative outcomes of patients undergoing oncological multivisceral or multi-tissue resection which involved concomitant resection of the upper digestive tract/organs (oesophagogastric and hepatopancreatic-biliary).

Methods

This is a retrospective cohort study of patients treated between May 2019 to May 2023 at the Royal Marsden Hospital, London, United Kingdom. All treatment decisions were ratified at tumour specific multidisciplinary team meetings (MDT).

Results

A total of twenty-two patients were included in this series. The mean age and BMI were 56.2 years and 26.5 kg/m2 respectively. 86% of patients had ASA Grade II and 91% had WHO performance status of zero or one. 59% of patients underwent some form of tumour specific neoadjuvant treatment prior to surgical resection. The indication for surgery was due to malignancies originating from the upper digestive tract (41%), gynaecological organs (32%) and urinary tract (22%). The majority of cases (68%) involved surgeons from two sperate surgical specialties. 91% of cases involved resection of at least three or more organs or soft tissue groups. The mean critical care length of stay and total length of hospital stay was 2.9 days and 17.8 days respectively. 41% patients required inpatient blood transfusion. Clavien-Dindo Grade II, III and IV complication rates were 68%, 14% and 0% respectively. There were no 30-day re-admissions and no 90-day mortalities. The mean duration of follow up was 23.7 months. At time of analysis, the median overall survival (OS) was 21.0 months.

Conclusions

Complex MVR can be performed safely with acceptable perioperative outcomes at specialist high-volume centres. To achieve these outcomes patients should be selected carefully on a case-by-case basis with discussion at all respective tumour specific MDTs.